Medical Technology

@xconomy.com 3 years ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 4 years ago

FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

@xconomy.com 4 years ago

Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More

@xconomy.com 5 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans

@xconomy.com 5 years ago

Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines